AIM ImmunoTech (AIM) Competitors $8.93 +0.28 (+3.18%) Closing price 03:56 PM EasternExtended Trading$8.93 0.00 (0.00%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIM vs. RANI, ENLV, SXTC, FBLG, EYEN, TPST, CARA, ALXO, GBIO, and TENXShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Rani Therapeutics (RANI), Enlivex Therapeutics (ENLV), China SXT Pharmaceuticals (SXTC), FibroBiologics (FBLG), Eyenovia (EYEN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), ALX Oncology (ALXO), Generation Bio (GBIO), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Its Competitors Rani Therapeutics Enlivex Therapeutics China SXT Pharmaceuticals FibroBiologics Eyenovia Tempest Therapeutics Cara Therapeutics ALX Oncology Generation Bio Tenax Therapeutics Rani Therapeutics (NASDAQ:RANI) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Do analysts recommend RANI or AIM? Rani Therapeutics currently has a consensus target price of $7.33, indicating a potential upside of 1,328.11%. AIM ImmunoTech has a consensus target price of $275.00, indicating a potential upside of 2,981.23%. Given AIM ImmunoTech's higher possible upside, analysts plainly believe AIM ImmunoTech is more favorable than Rani Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, RANI or AIM? AIM ImmunoTech has lower revenue, but higher earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRani Therapeutics$1.03M28.66-$30.02M-$0.99-0.52AIM ImmunoTech$146K46.70-$28.96M-$24.00-0.37 Which has more risk & volatility, RANI or AIM? Rani Therapeutics has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Do insiders & institutionals have more ownership in RANI or AIM? 30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 53.3% of Rani Therapeutics shares are owned by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is RANI or AIM more profitable? Rani Therapeutics has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. AIM ImmunoTech's return on equity of -421.73% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rani TherapeuticsN/A -1,258.76% -80.52% AIM ImmunoTech -12,594.21%-421.73%-147.54% Does the media refer more to RANI or AIM? In the previous week, Rani Therapeutics and Rani Therapeutics both had 1 articles in the media. Rani Therapeutics' average media sentiment score of 1.89 beat AIM ImmunoTech's score of -0.71 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Rani Therapeutics Very Positive AIM ImmunoTech Negative SummaryRani Therapeutics beats AIM ImmunoTech on 8 of the 13 factors compared between the two stocks. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.82M$200.82M$5.52B$20.44BDividend YieldN/AN/A5.36%3.76%P/E Ratio-18.99N/A26.3127.62Price / Sales46.70236.07409.0236.30Price / CashN/A22.4425.8817.85Price / Book44.635.567.914.55Net Income-$28.96M-$96.61M$3.15B$984.47M7 Day Performance-4.03%2.70%0.95%1.83%1 Month Performance-2.35%5.74%5.25%4.99%1 Year Performance-75.58%15.88%32.63%14.00% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech1.6056 of 5 stars$8.93+3.2%$275.00+2,981.2%-76.8%$6.82M$146K-18.9920Gap UpRANIRani Therapeutics2.2329 of 5 stars$0.50-0.4%$7.33+1,381.5%-86.5%$28.57M$1.20M-0.50110Positive NewsENLVEnlivex Therapeutics3.3083 of 5 stars$1.17-1.7%$10.00+754.7%-21.1%$27.69MN/A-1.7770SXTCChina SXT Pharmaceuticals0.4734 of 5 stars$1.74-3.9%N/A-80.2%$27.54M$1.93M0.0090FBLGFibroBiologics2.9721 of 5 stars$0.72-4.1%$13.00+1,718.2%-87.5%$27.51MN/A-3.4210EYENEyenovia1.0113 of 5 stars$9.31+3.2%$2.00-78.5%-78.2%$27.09M$60K-0.1640Gap UpHigh Trading VolumeTPSTTempest Therapeutics1.8219 of 5 stars$7.08+0.5%$30.00+324.0%-76.1%$26.02MN/A-0.3920News CoverageCARACara Therapeutics0.3316 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeALXOALX Oncology2.9815 of 5 stars$0.46+0.6%$3.30+620.5%-93.1%$24.30MN/A-0.1840Positive NewsGBIOGeneration Bio3.4436 of 5 stars$0.36-2.8%$7.33+1,937.0%-88.6%$24.13M$19.89M-0.33150TENXTenax Therapeutics1.4306 of 5 stars$5.86+2.3%$17.50+198.6%+91.1%$24.07MN/A-2.349 Related Companies and Tools Related Companies RANI Alternatives ENLV Alternatives SXTC Alternatives FBLG Alternatives EYEN Alternatives TPST Alternatives CARA Alternatives ALXO Alternatives GBIO Alternatives TENX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AIM) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
